AAAAAA
Results:
1-21
|
Results: 21
Authors:
Shulman, NS
Machekano, RA
Shafer, RW
Winters, MA
Zolopa, AR
Liou, SH
Hughes, M
Katzenstein, DA
Citation: Ns. Shulman et al., Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy, J ACQ IMM D, 27(4), 2001, pp. 377-380
Authors:
Kantor, R
Machekano, R
Gonzales, MJ
Dupnik, K
Schapiro, JM
Shafer, RW
Citation: R. Kantor et al., Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs, NUCL ACID R, 29(1), 2001, pp. 296-299
Authors:
Shulman, N
Zolopa, AR
Passaro, D
Shafer, RW
Huang, W
Katzenstein, D
Israelski, DM
Hellmann, N
Petropoulos, C
Whitcomb, J
Citation: N. Shulman et al., Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy, AIDS, 15(9), 2001, pp. 1125-1132
Authors:
Smeaton, LM
DeGruttola, V
Robbins, GK
Shafer, RW
Citation: Lm. Smeaton et al., ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1, CONTR CL TR, 22(2), 2001, pp. 142-159
Authors:
Shafer, RW
Hertogs, K
Zolopa, AR
Warford, A
Bloor, S
Betts, BJ
Merigan, TC
Harrigan, R
Larder, BA
Citation: Rw. Shafer et al., High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients, J CLIN MICR, 39(4), 2001, pp. 1522-1529
Authors:
Gonzales, MJ
Machekano, RN
Shafer, RW
Citation: Mj. Gonzales et al., Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population, J INFEC DIS, 184(8), 2001, pp. 998-1006
Authors:
Shulman, NS
Zolopa, AR
Passaro, DJ
Murlidharan, U
Israelski, DM
Brosgart, CL
Miller, MD
Van Doren, S
Shafer, RW
Katzenstein, DA
Citation: Ns. Shulman et al., Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response, J ACQ IMM D, 23(3), 2000, pp. 221-226
Authors:
Shafer, RW
Jung, DR
Betts, BJ
Citation: Rw. Shafer et al., Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries, NAT MED, 6(11), 2000, pp. 1290-1292
Authors:
Shafer, RW
Deresinski, SC
Citation: Rw. Shafer et Sc. Deresinski, Human immunodeficiency virus on the Web: A guided tour, CLIN INF D, 31(2), 2000, pp. 568-577
Authors:
Batra, M
Tien, PC
Shafer, RW
Contag, CH
Katzenstein, DA
Citation: M. Batra et al., HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe, AIDS RES H, 16(10), 2000, pp. 973-979
Authors:
Shafer, RW
Jung, DR
Betts, BJ
Xi, YO
Gonzales, MJ
Citation: Rw. Shafer et al., Human immunodeficiency virus reverse transcriptase and protease sequence database, NUCL ACID R, 28(1), 2000, pp. 346-348
Authors:
Shafer, RW
Warford, A
Winters, MA
Gonzales, MJ
Citation: Rw. Shafer et al., Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals, J VIROL MET, 86(2), 2000, pp. 143-153
Authors:
Demeter, LM
Shafer, RW
Meehan, PM
Holden-Wiltse, J
Fischl, MA
Freimuth, WW
Para, MF
Reichman, RC
Citation: Lm. Demeter et al., Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260), ANTIM AG CH, 44(3), 2000, pp. 794-797
Authors:
Shafer, RW
Chuang, TK
Hsu, P
White, CB
Katzenstein, DA
Citation: Rw. Shafer et al., Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe, AIDS RES H, 15(1), 1999, pp. 65-69
Authors:
Shafer, RW
Vuitton, DA
Citation: Rw. Shafer et Da. Vuitton, Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1, BIOMED PHAR, 53(2), 1999, pp. 73-86
Authors:
Shafer, RW
Stevenson, D
Chan, B
Citation: Rw. Shafer et al., Human immunodeficiency virus reverse transcriptase and protease sequence database, NUCL ACID R, 27(1), 1999, pp. 348-352
Authors:
Palmer, S
Shafer, RW
Merigan, TC
Citation: S. Palmer et al., Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development, AIDS, 13(6), 1999, pp. 661-667
Authors:
Palmer, S
Shafer, RW
Merigan, TC
Citation: S. Palmer et al., Hydroxyurea enhances the activities of didanosine, 9-[2(phosphonylmethoxy)ethyl] adenine, and 9-[2(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates, ANTIM AG CH, 43(8), 1999, pp. 2046-2050
Authors:
Shafer, RW
Hsu, P
Patick, AK
Craig, C
Brendel, V
Citation: Rw. Shafer et al., Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors, J VIROLOGY, 73(7), 1999, pp. 6197-6202
Authors:
Zolopa, AR
Shafer, RW
Warford, A
Montoya, JG
Hsu, P
Katzenstein, D
Merigan, TC
Efron, B
Citation: Ar. Zolopa et al., HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed, ANN INT MED, 131(11), 1999, pp. 813
Authors:
Shafer, RW
Winters, MA
Palmer, S
Merigan, TC
Citation: Rw. Shafer et al., Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients (vol 128, pg 906, 1998), ANN INT MED, 129(12), 1998, pp. 1083-1083
Risultati:
1-21
|